Nkarta presents new preclinical data from engineered nk cell platform at aacr annual meeting 2022

South san francisco, calif., april 08, 2022 (globe newswire) -- nkarta, inc. (nasdaq: nktx), a biopharmaceutical company developing engineered natural killer (nk) cell therapies to treat cancer, today announced the presentation of four preclinical data abstracts focused on its natural killer cell platform and pipeline at the american association for cancer research (aacr) annual meeting 2022.
NKTX Ratings Summary
NKTX Quant Ranking